全文获取类型
收费全文 | 38087篇 |
免费 | 3319篇 |
国内免费 | 1737篇 |
专业分类
耳鼻咽喉 | 434篇 |
儿科学 | 662篇 |
妇产科学 | 660篇 |
基础医学 | 4637篇 |
口腔科学 | 693篇 |
临床医学 | 4090篇 |
内科学 | 6129篇 |
皮肤病学 | 878篇 |
神经病学 | 2498篇 |
特种医学 | 1331篇 |
外国民族医学 | 14篇 |
外科学 | 4652篇 |
综合类 | 5116篇 |
现状与发展 | 5篇 |
一般理论 | 20篇 |
预防医学 | 2457篇 |
眼科学 | 1335篇 |
药学 | 3195篇 |
21篇 | |
中国医学 | 1436篇 |
肿瘤学 | 2880篇 |
出版年
2023年 | 464篇 |
2022年 | 558篇 |
2021年 | 1622篇 |
2020年 | 1207篇 |
2019年 | 1219篇 |
2018年 | 1322篇 |
2017年 | 1150篇 |
2016年 | 1160篇 |
2015年 | 1518篇 |
2014年 | 1901篇 |
2013年 | 1828篇 |
2012年 | 2732篇 |
2011年 | 2803篇 |
2010年 | 1655篇 |
2009年 | 1380篇 |
2008年 | 1990篇 |
2007年 | 2102篇 |
2006年 | 2010篇 |
2005年 | 1936篇 |
2004年 | 1615篇 |
2003年 | 1505篇 |
2002年 | 1345篇 |
2001年 | 1113篇 |
2000年 | 1001篇 |
1999年 | 876篇 |
1998年 | 488篇 |
1997年 | 427篇 |
1996年 | 322篇 |
1995年 | 331篇 |
1994年 | 252篇 |
1993年 | 189篇 |
1992年 | 318篇 |
1991年 | 306篇 |
1990年 | 293篇 |
1989年 | 267篇 |
1988年 | 227篇 |
1987年 | 217篇 |
1986年 | 213篇 |
1985年 | 164篇 |
1984年 | 119篇 |
1983年 | 86篇 |
1982年 | 53篇 |
1981年 | 57篇 |
1980年 | 48篇 |
1979年 | 82篇 |
1978年 | 60篇 |
1977年 | 61篇 |
1974年 | 66篇 |
1973年 | 61篇 |
1972年 | 64篇 |
排序方式: 共有10000条查询结果,搜索用时 223 毫秒
1.
2.
3.
4.
Yan Gao Shi-Feng Chu Zhao Zhang Qi-Di Ai Cong-Yuan Xia Hui-Yong Huang 《Journal of Asian natural products research》2019,21(8):782-797
Inappropriate use of acetaminophen (APAP) can lead to morbidity and mortality secondary to hepatic necrosis. Ginsenoside Rg1 is a major active ingredient in processed Panax ginseng, which is proved to elicit biological effects. We hypothesized the beneficial effect of Rg1 on APAP-mediated hepatotoxicity was through Nrf2/ARE pathway. The study was conducted in cells and mice, comparing the actions of Rg1. Rg1 significantly improved cell survival rates and promoted the expression of antioxidant proteins. Meanwhile, Rg1 reduced the excessive ROS and the occurrence of cell apoptosis, which were related to Nrf2/ARE pathway. Expression of Nrf2 has a certain cell specificity.
5.
Feng Wang Dachuan Wang Bingyi Tan Jun Dong Rongjie Feng Zenong Yuan Naiguo Wang 《Medicine》2015,94(39)
The present study aimed at examining the curative effect of modified posterior operation on treatment of Kümmell''s disease.About 30 patients of Kümmell''s disease with complete image and clinical data treated during June 2004 to July 2013 were conducted with anterior and posterior approaches, respectively. Kyphotic Cobb angle, fractured vertebra wedge angle, and the anterior and posterior heights of fractured vertebra were all measured through x-ray before and after operation, and the pain visual analog scale (VAS) was determined for evaluating the effect of operations. The injury and restoration of neurological function were assessed using Frankel classification.Patients in group A were treated with anterior operation, whereas group B was posterior operation. Postoperatively, VAS score, kyphotic Cobb angle, anterior vertebra height, and pathologic vertebra wedge angle were all significantly improved in patients with Kümmell''s disease receiving modified posterior operation (group B). Similar results were also observed in patients with anterior operation. The improvement of VAS and correction rate of kyphotic Cobb angle indicated equivalent effects of posterior and anterior operations. Meanwhile, alleviated neurological function damage was observed in 2 groups. Relevant factor analysis illustrated that there was no significant correlation of the severity and improvement rate of pain symptoms with age, medical history, anterior and posterior vertebra heights, kyphotic Cobb angle, and pathological vertebra wedge angle.Compared with traditional anterior approach, modified posterior operation, adopting transpedicular vertebral body grafting combined with vertebral pedicle screw fixation, could produce equivalent effects on kyphosis correction, pain relief, and improvement of neurological function in patients with Kümmell''s disease. 相似文献
6.
7.
Bo Cai Qiyun Sun Jianhui Qiao Changlin Yu Kaixun Hu Tieqiang Liu Bingxia Li Yajing Huang Yi Wang Hongli Zuo Zheng Dong Yaqing Lei Zhiqing Liu Bo Yao Caixia Li Huisheng Ai Mei Guo 《American journal of cancer research》2020,10(11):3852
Patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) have poor prognosis, and the efficacy of chemotherapy plus tyrosine kinase inhibitors (TKIs) followed by mismatched donor stem cell infusion (microtransplantation, MST) has not been determined. We retrospectively summarized 45 patients including 11 undergoing MST with TKIs, 17 receiving allogeneic transplant and 17 undergoing chemotherapy with TKIs. Improved 4-year overall survival rate was observed in the MST group (91%) compared with either transplant group (31%, P = .005) or chemotherapy group (36%, P = .013). The MST group also had higher 2-year and 4-year leukemia-free survival rates (91% and 72%, respectively) compared with either transplant group (33%, P = .005 and 33%, P = .021, respectively) or chemotherapy group (41%, P = .017 and 31%, P = .023, respectively). 2-year and 4-year cumulative incidences of hematologic relapse were lower in the MST group (9% and 28%, respectively) compared with those in the chemotherapy group (56%, P = .025 and 67%, P = .034, respectively). In patients undergoing MST, donor microchimerism was detected (1.07 × 10-5 to 6.6 × 10-4 copies from 9 to 1499 days) in 7 patients, and donor/patient-derived HLA*0201/2402+WT1+CD8+ T cells were found from 0.05% to 0.67% in 6 patients. MST may provide a favorable treatment for patients with Ph+ ALL. 相似文献
8.
Whitney S. Brandt Wanpu Yan Jian Zhou Kay See Tan Joseph Montecalvo Bernard J. Park Prasad S. Adusumilli James Huang Matthew J. Bott Valerie W. Rusch Daniela Molena William D. Travis Mark G. Kris Jamie E. Chaft David R. Jones 《The Journal of thoracic and cardiovascular surgery》2019,157(2):743-753.e3
Objective
Comparative survival between neoadjuvant chemotherapy and adjuvant chemotherapy for patients with cT2-4N0-1M0 non–small cell lung cancer has not been extensively studied.Methods
Patients with cT2-4N0-1M0 non–small cell lung cancer who received platinum-based chemotherapy were retrospectively identified. Exclusion criteria included stage IV disease, induction radiotherapy, and targeted therapy. The primary end point was disease-free survival. Secondary end points were overall survival, chemotherapy tolerance, and ability of Response Evaluation Criteria In Solid Tumors response to predict survival. Survival was estimated using the Kaplan–Meier method, compared using the log-rank test and Cox proportional hazards models, and stratified using matched pairs after propensity score matching.Results
In total, 330 patients met the inclusion criteria (n = 92/group after propensity-score matching; median follow-up, 42 months). Five-year disease-free survival was 49% (95% confidence interval, 39-61) for neoadjuvant chemotherapy versus 48% (95% confidence interval, 38-61) for adjuvant chemotherapy (P = .70). On multivariable analysis, disease-free survival was not associated with neoadjuvant chemotherapy or adjuvant chemotherapy (hazard ratio, 1.1; 95% confidence interval, 0.64-1.90; P = .737), nor was overall survival (hazard ratio, 1.21; 95% confidence interval, 0.63-2.30; P = .572). The neoadjuvant chemotherapy group was more likely to receive full doses and cycles of chemotherapy (P = .014/0.005) and had fewer grade 3 or greater toxicities (P = .001). Response Evaluation Criteria In Solid Tumors response to neoadjuvant chemotherapy was associated with disease-free survival (P = .035); 15% of patients receiving neoadjuvant chemotherapy (14/92) had a major pathologic response.Conclusions
Timing of chemotherapy, before or after surgery, is not associated with an improvement in overall or disease-free survival among patients with cT2-4N0-1M0 non–small cell lung cancer who undergo complete surgical resection. 相似文献9.
10.
谈伟来 《健康教育与健康促进》2020,15(2):188-189
目的了解某社区第二类疫苗接种及疑似预防接种异常反应(AEFI)情况。方法通过查询疫苗出入库系统和中国免疫规划信息管理系统,对2019年该社区第二类疫苗使用及AEFI报告情况进行分析。结果2019年,该社区接种门诊共接种第二类疫苗21种7449剂,接种数最多的是13价肺炎疫苗(784剂)。接种数居前6位的依次为13价肺炎疫苗、ACYW135群流脑多糖疫苗、轮状病毒疫苗、百白破-IPV-HIB五联疫苗、手足口EV71疫苗、九价人乳头瘤疫苗。累计报告AEFI病例94例,发生率为1.26%;一般反应占96.81%,异常反应占3.19%。报告AEFI疫苗共12种,报告发生率居前6位的分别为13价肺炎疫苗、百白破-IPV-HIB五联疫苗、百白破-IPV-HIB四联疫苗、手足口EV71疫苗、九价HPV疫苗、AC结合流脑疫苗。结论第二类疫苗品种接种量均有所增加,AEFI报告发生率有所波动,需加强监测。 相似文献